Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Pharmacodynamics in Gastric Bypass
NCT02058199Phase 1Terminated
- Sponsor
- Upstate Medical University
- Start
- Dec 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivaroxaban in venous thromboembolism (VTE) (4 arms), sponsored by Upstate Medical University. Primary endpoint: Median inhibition of Factor Xa at 24 hours. Started Dec 2014; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02058199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058199.